Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Viking Holdings Ltd. is banking on affluent customers to see it through this period of jitters in the travel industry.While ...

Viking Cruises' unique ship designs, being small and almost identical, set the company apart and serve as an important value ...

Goldman Sachs analyst Lizzie Dove reiterated a Neutral rating on the shares of Viking Holdings Ltd (NYSE:VIK) and raised the ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Viking Holdings (NYSE:VIK) reports robust Q4 growth with a 20.5% sales surge and plans to expand in 2025. Discover key ...

Viking set new booking and revenue records, continuing strong performance from 2024, with high demand and successful ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

For our Core Products, operating capacity is 12% higher for the 2025 season compared to the 2024 season. As of February 23 for our Core ...